Key Sessions
Simone Zanetti
Case Study: Potency Strategy and Regulatory Interactions for Hemgenix
CSL Behring
keyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
Thursday 5th November – Day 2 Main Conference - GMT (Greenwich Mean Time, GMTZ)
keyboard_arrow_leftSearch & Filter
search
Streams
Thursday 5th November – Day 2 Main Conference - GMT (Greenwich Mean Time, GMTZ)
search
Streams
Showing 1 of 1 Streams
Registration
08:30 - 09:00
Registration & Morning Coffee
Showing 4 of 4 Streams
Cell Therapy Manufacturing & Analytics
Gene Therapy Manufacturing & Analytics
Exosomes Europe
LNPs Europe
09:00 - 09:10
Chairperson’s Opening Remarks: Cell Therapy Manufacturing & Analytics
- Catherine Simpson - Conference Director - Cell and Gene Therapy Portfolio, Informa Connect LifeSciences
09:10 - 09:40
Bridging Viral and Lipid Nanoparticle Worlds: Surface Engineering Lentiviral Vector-Based Nanoparticles for Targeted In Situ CAR-T Cell Therapy
- Céline Jaudouin - Senior Formulation Scientist, Alaya.bio
09:40 - 10:40
Panel Discussion: Scale-Up Strategies: Navigating the Road Ahead for In Vivo CAR-T
- Lorenz Mayr - Managing Director, BioMedTech Consulting GmbH
- Matthias Bozza - Director, Head of Strategy and R&D, CPTx
- Ulf Grawunder - Co-founder & CEO, T-CURX
09:00 - 09:10
Chairperson’s Opening Remarks: Gene Therapy Manufacturing & Analytics
- Christine Le Bec - Deputy CTO, Head of Analytical Development & QC, Sensorion
09:10 - 09:40
Manufacturing Challenges and Control Strategies For Dual AAV Vectors - Characterisation and Analytical Methods
- Christine Le Bec - Deputy CTO, Head of Analytical Development & QC, Sensorion
09:40 - 10:10
Case Study: Potency Strategy and Regulatory Interactions for Hemgenix
- Simone Zanetti - Global Head of QC Analytical Technologies, Gene Therapy, CSL Behring
10:10 - 10:40
Mastering hcDNA: A Harmonized Approach for AAV Gene Therapies
- Nic Preyat - Associate Director, Process Sciences, CMC Development - Gene Therapy, UCB
09:05 - 09:10
Chairperson's Opening Remarks: Exosomes Europe 2026
- Robert Mamoun - CEO, Ciloa
09:10 - 09:40
Smart EV Biomanufacturing: Balancing Yield, Purity & Scale from Lab to Clinic
- Jan Schrooten - CEO, Antleron
09:40 - 09:55
Towards scalable and robust EV production in membrane-aerated 3D bioreactors with chemically defined media
- Tim Milfeit - PhD Candidate (M.Sc.), University Hospital Essen - Group for Translational Vesicle Research by Prof. Dr. B. Giebel
09:55 - 10:40
Please Move to Another Track
09:10 - 09:40
ROOM EUROPA 6: Bridging Viral and Lipid Nanoparticle Worlds: Surface Engineering Lentiviral Vector-Based Nanoparticles for Targeted In Situ CAR-T Cell Therapy
- Céline Jaudouin - Senior Formulation Scientist, Alaya.bio
09:40 - 10:40
ROOM EUROPA 6: Panel Discussion: Scale-Up Strategies: Navigating the Road Ahead for In Vivo CAR-T
- Lorenz Mayr - Managing Director, BioMedTech Consulting GmbH
- Matthias Bozza - Director, Head of Strategy and R&D, CPTx
- Ulf Grawunder - Co-founder & CEO, T-CURX
Showing 2 of 2 Streams
Break
Poster Viewing - Meet the Poster Presenters
10:40 - 11:20
Morning Coffee and Networking Break in Exhibition Hall
10:40 - 11:20
Poster Viewing - Meet the Poster Presenters
Explore groundbreaking research, meet the poster presenters and ask your questions.
Showing 4 of 4 Streams
Cell Therapy Manufacturing & Analytics
Gene Therapy Manufacturing & Analytics
Exosomes Europe
LNPs Europe
11:20 - 11:50
Use Cases of PAT Integration in CGT Processes and Implementation of Advanced Control Strategies
- Rolando Matos - Senior Scientist, Cell and Gene Therapy Catapult
11:50 - 12:20
5 Opportunities for AI Integration in Process Development
- Stefan Bostock - CEO & Co-Founder, Danu Insights
12:20 - 12:50
Navigating the Evolving European Regulatory Landscape for Cell and Gene Therapies
- Paolo Morgese - VP Public Affairs EMEA, Alliance for Regenerative Medicine
11:20 - 11:50
ROOM EUROPA 6: Use Cases of PAT Integration in CGT Processes and Implementation of Advanced Control Strategies
- Rolando Matos - Senior Scientist, Cell and Gene Therapy Catapult
11:50 - 12:20
ROOM EUROPA 6: 5 Opportunities for AI Integration in Process Development
- Stefan Bostock - CEO & Co-Founder, Danu Insights
12:20 - 12:50
ROOM EUROPA 6: Navigating the Evolving European Regulatory Landscape for Cell and Gene Therapies
- Paolo Morgese - VP Public Affairs EMEA, Alliance for Regenerative Medicine
11:20 - 11:50
EVerGel: Our Current Journey Toward the Clinic
- Clément Bonamy - Head of R&D Platform, Everzom
11:50 - 12:20
Manufacturing, regulatory compliance, and clinical development of EXO-101
- Andreia Silva - Head of Research, Exogenus Therapeutics
12:20 - 12:50
Genetically Programmed Extracellular Vesicles for Cell Targeting and Novel Therapeutic Development
- Christopher Locher - CEO & Co-Founder, Versatope, USA
11:20 - 11:25
Chairperson
- Christian Reinsch - Vice President Technology Profiling, BioNTech SE
11:25 - 11:55
Enabling LNP-DNA Delivery to Target Peripheral Nerve Diseases
- Gonzalo Fernández-Miranda - CEO and Co-Founder, CureAge Therapeutics
11:55 - 12:25
Targeted Lipid Nanoparticles Deliver Immune-Silent ssDNA to Generate CAR T Cells
- Matthias Bozza - Director, Head of Strategy and R&D, CPTx
12:25 - 12:55
R&D Innovations: Case Studies Next-Generation Therapeutic Applications of LNPs
- Katia Lemdani - Director Research and Development, Neovacs
Showing 1 of 1 Streams
Break
12:55 - 14:00
Networking Lunch in the Exhibition Hall
Showing 3 of 3 Streams
Cell Therapy Innovation Showcase
Gene Therapy Innovation Showcase
Exosomes Europe
14:00 - 14:05
Chairperson
- Nicole Lund - Senior Director of Analytical & Quality Control, BlueRock Therapeutics
14:05 - 14:35
Off-The-Shelf Immune-Shielded iPSC-Derived Armored CAR γδ T Cells as a Novel Cell Therapy to Treat Hepatocellular Carcinoma
- Stephanie Sontag - Senior Research Scientist, Evotec International GmbH
14:35 - 14:55
Cell Therapy Innovation Showcase: Captain T Cell
- Alberto Sada Japp - Senior Director - R&D, Captain T Cell
14:55 - 15:15
ImmunoKey Ltd -Engineering Tumour Selectivity into Multi-Antigen CAR T-Cell Therapy. CARKey; A Dual-Receptor Platform for Solid Tumours
- Gray Kueberuwa - Chief Executive Officer, ImmunoKey Ltd
15:15 - 15:35
NeutroGen Therapeutics- Restoring Innate Immunity: Developing Off-the-Shelf Neutrophil Transfusions for Severe Neutropenia
- Lorenz Knackstedt - Chief Technology Officer, NeutroGen Therapeutics
14:00 - 14:05
Chairperson
- Marion Hitchcock - Managing Director Gene & Cell Therapies Incubator Berlin and R&D Strategy & Portfolio Manager, Bayer
14:05 - 14:25
Ikarovec - Development Of A Dual-Pathway Gene Therapy for Blindness
- Andy Osborne - Vice President of Pre-Clinical Research, Ikarovec
14:25 - 14:45
Kindling Bio - Igniting Cancer Gene Therapy: Delivering Impact For Children and Beyond
- Aleck Jones - CEO, Kindling Bio
14:45 - 15:05
Gene Therapy Innovation Showcase: EpiBlok Therapeutics GmbH
- Regine Heilbronn - Co-Founder and CEO, EpiBlok Therapeutics
15:05 - 15:25
CREATe Therapeutics: A First-In-Class Drug-Controlled CNS Gene Therapy with PoC in Focal Epilepsy
- Tamás Kitka - Founder, Managing Director, CREATe Therapeutics
14:00 - 14:05
Chair Remarks
- Robert Mamoun - CEO, Ciloa
14:05 - 14:35
Like Parent, Like Vesicle? Can MSC-Derived EVs Surpass Parent Cells' Clinical Roadblocks? First-in-Human Evidence.
- Maroun Khoury, PhD - CSO, Executive Director, Full Professor, EVast BIO /Cells for Cells / IMPACT center
14:35 - 15:05
Development of DB503, an engineered TSG-6 exosome therapeutic for Traumatic Brain Injury
- Mickey Pentecost - CEO, Founder & Board Director, Diadem Biotherapeutics
Showing 1 of 1 Streams
Break
15:35 - 16:05
Afternoon Coffee and Networking Break in Exhibition Hall
16:05 - 16:10
Close of Event 2026 – Thanks for Coming!
Get the Latest Event Updates
Sign up to get the latest event updates and information.
Filter
Streams
